APRN Pharmacology Today: Optimal Treatment for Dyslipidemia
Dr. Joel C. Marrs, PharmD, FCCP, FASHP, FNLA, BCPS-AQ Cardiology, BCACP, CLS, ASH-CHC
This interactive online course uses the latest evidence-based resources to help you select medications for the treatment of dyslipidemia, focusing on thorough reviews to help improve patient treatment plans.
With dyslipidemia being a primary, major risk factor for atherosclerotic cardiovascular disease (ASCVD) death in 2016, it’s important to learn more about this condition. Causing abnormal elevated cholesterol or fats (lipids) in the blood, dyslipidemia can increase the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns.
Are you ready to learn the latest on optimal pharmacological management for patients with dyslipidemia?
In this new APRN Pharmacology Today course, discover available drug treatments for dyslipidemia, current clinical practice guidelines, standards of care, and therapeutic options to improve treatment. This interactive online course uses the latest evidence-based resources to help you select medications for the treatment of dyslipidemia, focusing on thorough reviews to help improve patient treatment plans.
Key Learning Outcomes
After taking this interactive online course, you will be able to:
- Describe risk factors and diagnostic criteria for dyslipidemia
- Review current literature and guideline recommendations for the treatment of dyslipidemia
- Compare and contrast the available pharmacologic treatments for dyslipidemia
- Formulate a treatment and monitoring plan for patients with dyslipidemia to decrease the risk of complications
- And much more!
Dr. Joel C. Marrs
PharmD, FCCP, FASHP, FNLA, BCPS-AQ Cardiology, BCACP, CLS, ASH-CHC
Dr. Joel Marrs is an Associate Professor in the Department of Clinical Pharmacy at the University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS). Dr. Marrs received his PharmD degree from Butler University. Following his PharmD degree, he completed a postgraduate year 1 (PGY1) pharmacy practice residency at Mount Carmel Medical Center in Columbus, Ohio and a PGY2 Family Medicine Specialty residency at the University of Colorado in Denver, Colorado. He is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Cardiology and a Board Certified Ambulatory Care Pharmacist. He is a Clinical Lipid Specialist recognized by the Accreditation Council for Clinical Lipidology. He is an American Society of Hypertension Certified Hypertension Clinician (ASH-CHC). He is Fellow of the American Society of Health-system Pharmacists (ASHP), the National Lipid Association (NLA) and the American College of Clinical Pharmacy (ACCP). Currently, he is president-elect of the Southwest Chapter of the NLA. In his current position, Dr. Marrs practices as a clinical pharmacy specialist with Denver Health in an internal medicine clinic where he focuses on cardiovascular and metabolic pharmacotherapy. His research interests are focused on the prevention and management of endocrine and cardiovascular disease and patient-centered outcomes research. He is the chair of the University of Colorado SSPPS curriculum committee.